Chr. Olesen Synthesis operates a cGMP-certified facility near Copenhagen that has maintained commercial production since 2015. The company focuses on the development and manufacturing of complex active pharmaceutical ingredients, specifically those utilized in treatments for opioid use disorder and ADHD. Its products currently reach pharmaceutical markets across Europe, North America, and the Middle East.
In section Releases
Samfara acquires Danish API manufacturer Chr. Olesen Synthesis
London-based life sciences investor Samfara has acquired Copenhagen-based Chr. Olesen Synthesis, a specialist manufacturer of controlled-substance APIs. The deal, which marks Samfara's first investment, involves a syndicate of institutional backers and family offices, though the financial terms of the transaction remain undisclosed by the parties involved.
Following the acquisition, Thomas Moestrup will remain as Chief Executive and continue to invest in the business alongside Samfara. Jean-François Hilaire, formerly of Unither and Recipharm, is set to join the company as Chair of the board. Samfara partners Helena Malchione and James Cocker stated that the acquisition aligns with their strategy of targeting high-potential companies in complex pharmaceutical niches. The new ownership intends to scale the business through both organic growth and potential future acquisitions.
Comments (0)
No comments yet. Be the first!